ArticleJournal of general internal medicine2026
Predictors of Newly Prescribed Medications for Alcohol Use Disorder Among Hospitalized Adults: A Retrospective Cohort Study.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcohol use disorder (AUD) is pervasive among hospitalized adults and associated with poor post-hospitalization outcomes. Medications for alcohol use disorder (MAUD) improve clinical outcomes, but prescribing rates at hospital discharge remain low. Factors associated with inpatient MAUD initiation are incompletely understood.
objectiveIdentification of patient-level and hospitalization-level factors associated with a new MAUD prescription at hospital discharge among adults with AUD.
designRetrospective cohort study. PATIENTS: Adults hospitalized with an AUD-related diagnosis between 2018 and 2023 at one of two hospitals within a large academic medical center without a dedicated inpatient addiction medicine consult service. MAIN MEASURES/OUTCOMES: The primary outcome was a new prescription of an FDA-approved MAUD at hospital discharge. Predictor variables were patient and hospitalization characteristics. Associations were measured using multivariable analyses, with generalized estimating equations accounting for patients with multiple hospitalizations. KEY
resultsThe cohort included 4232 hospitalizations among 2347 patients. New MAUD were prescribed at discharge in 467 hospitalizations (11%). In the multivariable analysis, a primary AUD diagnosis was the only patient-level factor associated with MAUD prescription (OR = 1.25; 95% CI 1.02-1.54). Hospitalization characteristics independently associated with MAUD prescription included longer length of stay (OR = 1.70 [1.33, 2.17], 1.47 [1.08, 2.02], and 1.37 [0.98, 1.91] for 3-4 days, 5-7 days, and 8 or more days relative to 0-2 days), consultation by care management (OR 1.37; 95% CI 1.02-1.85), and discharge from a general medicine teaching or family medicine service (OR = 1.41 [1.09, 1.83], and OR = 2.07 [1.52, 2.81]) respectively relative to HIM non-teaching team.
conclusionsMAUD prescribing at hospital discharge remains low. However, several hospitalization-level factors were associated with higher prescribing rates, suggesting that service structure and consultative support may represent targets for interventions to improve evidence-based treatment of AUD.
Indexed as
Identifiers
42918933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.